Egyptian Atherosclerosis and Vascular Biology Association Consensus on the Use of Sodium Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction
AbstractHeart failure (HF) is a common cause of cardiovascular mortality and morbidity. Despite advances in treatment, the prognosis remains poor. Sodium-glucose co-transporter 2 (SGLT-2) inhibitors decrease HF events by 27 –39% in high-risk patients with type 2 diabetes mellitus (T2DM). Moreover, the DAPA-HF and EMPEROR-Reduced studies randomized patients with HF with reduced ejection fraction (HFrEF) with or without diabetes mellitus to receive guideline-directed medical therapy versus guideline-directed medical th erapy plus an SGLT-2 inhibitor. Both studies showed the benefits of SGLT-2 inhibitors. In addition, SGLT-...
Source: Clinical Drug Investigation - November 15, 2021 Category: Drugs & Pharmacology Source Type: research
Acknowledgement to Referees
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - November 11, 2021 Category: Drugs & Pharmacology Source Type: research
Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS
ConclusionsThese results demonstrate a novel approach to summarize adverse events in clinical trials, where the cumulative burden of class-specific risks describes the emerging safety profile of a new drug in clinical development, relative to reactions anticipated for drugs in an established pharmacological class.ClinicalTrials.gov IdentifiersNCT0296938, NCT00088634, NCT00549718, NCT00615433, NCT00790192. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - November 9, 2021 Category: Drugs & Pharmacology Source Type: research
Adherence to Desvenlafaxine Versus Usual Care and Its Impact on Health Outcomes: A Comparative Real-world Clinical Study
ConclusionsDesvenlafaxine is significantly associated with a higher adherence rate at 12 months compared to usual care based on SSRI or other SNRI. This suggests that desvenlafaxine could improve disease management having a positive impact on disease-associated costs. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - November 6, 2021 Category: Drugs & Pharmacology Source Type: research
Subcutaneous Infliximab, CT-P13 SC: A Profile of Its Use in the EU
AbstractCT-P13 (Remsima®; Inflectra®), a biosimilar of reference infliximab (Remicade®), provides a useful alternative for patients requiring infliximab therapy and, as with other biosimilar agents, has the potential to reduce treatment costs. Furthermore, the availability of CT-P13 in a subcutaneous formulation (CT-P13 SC), with the possibility (after adequate training) of self-administration at home, has the potential to both improve patient convenience and reduce the burden on the healthcare system. The initial approval of CT-P13 SC, for use in the treatment of rheumatoid arthritis in adults, was based on the find...
Source: Clinical Drug Investigation - November 2, 2021 Category: Drugs & Pharmacology Source Type: research
Efficacy of Interferon- β in Moderate-to-Severe Hospitalised Cases of COVID-19: A Systematic Review and Meta-analysis
ConclusionAddition of interferon- β to standard of care resulted in significant reduction in time to clinical improvement but no significant benefit in terms of reduction in mortality and length of hospital stay in moderate-to-severe cases of COVID-19. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - October 23, 2021 Category: Drugs & Pharmacology Source Type: research
Improved Therapeutic Approaches are Needed to Manage Graft-versus-Host Disease
AbstractAllogeneic haematopoietic stem cell transplantation (alloHSCT) offers a potentially curative therapy for patients suffering from diseases of the haematopoietic system but requires a high level of expertise and is both resource intensive and expensive. A frequent and life-threatening complication is graft-versus-host disease (GvHD). Acute GvHD (aGvHD) generally causes skin, gastrointestinal and liver symptoms, but chronic GvHD (cGvHD) has a different pathophysiology and may affect nearly every organ or tissue of the body. In Europe, GvHD prophylaxis is generally a calcineurin inhibitor in combination with methotrexa...
Source: Clinical Drug Investigation - October 16, 2021 Category: Drugs & Pharmacology Source Type: research
The Intraoperative Median Effective Dose of Oxytocin for Preventing Uterine Atony in Parturients with a Prior History of Caesarean Delivery
ConclusionThe initial bolus dose of oxytocin needed to prevent uterine atony was higher in parturients with prior caesarean delivery than in parturients without prior caesarean delivery. Uterine scarring may contribute to the increased oxytocin requirements of the former group.Trial Registration NumberChiCTR1900023474; investigator: Wei CN; date of registration: 30 May 2019. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - October 16, 2021 Category: Drugs & Pharmacology Source Type: research
First-in-Human, Single-Ascending Dose and Food Effect Studies to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cetagliptin, a Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
ConclusionsCetagliptin inhibited plasma dipeptidyl peptidase-4 activity, increased levels of active glucagon-like peptide-1 and was well tolerated at single doses up to 400 mg, eliciting no dose-limiting toxicity in healthy volunteers. Food did not affect the pharmacokinetics of cetagliptin.Clinical Trial RegistrationThe studies were registered athttp://www.chinadrugtrials.org.cn (Nos. CTR20180167 and CTR20181331). (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - October 16, 2021 Category: Drugs & Pharmacology Source Type: research
Health Economic Assessment of Optimal Biological Treatment for Moderate-to-Severe Psoriasis
ConclusionsThis research suggests that the optimal first-line treatment in the UK is adalimumab biosimilar. The optimal second-line and third-line treatments depend on the magnitude of confidential discounts applied to the biologic treatments. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - October 16, 2021 Category: Drugs & Pharmacology Source Type: research
Effectiveness and Safety of Dabigatran Compared to Vitamin K Antagonists in Non-Asian Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis
ConclusionsDabigatran has a favorable impact on effectiveness and safety outcomes compared with vitamin K antagonists in real-world populations. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - October 13, 2021 Category: Drugs & Pharmacology Source Type: research
Can Adherence to and Persistence with Inhaled Long-acting Bronchodilators Improve the Quality of Life in Patients with Chronic Obstructive Pulmonary Disease? Results from a German Disease Management Program
ConclusionsOverall, ILAB users significantly profited from PDC ≥ 80%, but not from continuous PDC or persistent days. In secondary subgroup analyses, patients with GOLD stage III and patients without heart failure particularly profited from PDC ≥ 80%. Only patients without heart failure particularly profited from more persistent days. Because identified effects were small and often not robust, advancing adherence and persistence alone may not improve the German DMP for COPD substantially. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - October 12, 2021 Category: Drugs & Pharmacology Source Type: research
The Cost-Effectiveness of a COVID-19 Vaccine in a Danish Context
ConclusionThe cost effectiveness of a COVID-19 vaccine is sensitive to whether or not productivity losses are included in the analyses. Without productivity losses, the elderly population should always be part of the target group for a COVID-19 vaccination programme. Taking productivity losses into account, at least in the case of low vaccine prices, vaccinating the younger population first can actually be cost effective. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - October 8, 2021 Category: Drugs & Pharmacology Source Type: research
Correction to: Spontaneous and Immune Checkpoint Inhibitor-Induced Autoimmune Diseases: Analysis of Temporal Information by Using the Japanese Adverse Drug Event Report Database
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - September 23, 2021 Category: Drugs & Pharmacology Source Type: research
Prescribing Trends of Biologic Disease-Modifying Anti-rheumatic Drugs Using a Claims Database from 6 Million People in Japan
ConclusionsThe increase in bDMARD monotherapy may be attributed to the new bDMARDs that have been launched sequentially; furthermore, physicians have come to recognise monotherapy as the mainstay of treatment. Future studies must accumulate evidence on the long-term efficacy and safety of bDMARDs. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - September 22, 2021 Category: Drugs & Pharmacology Source Type: research
